Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)

被引:854
|
作者
Cook, Nancy R. [1 ]
Cutler, Jeffrey A.
Obarzanek, Eva
Buring, Julie E.
Rexrode, Kathryn M.
Kumanyika, Shiriki K.
Appel, Lawrence J.
Whelton, Paul K.
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
[2] NHLBI, Bethesda, MD 20892 USA
[3] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Loyola Univ Hlth Syst, Maywood, IL USA
来源
BMJ-BRITISH MEDICAL JOURNAL | 2007年 / 334卷 / 7599期
关键词
D O I
10.1136/bmj.39147.604896.55
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To examine the effects of reduction in dietary sodium intake on cardiovascular events using data from two completed randomised trials, TOHP I and TOHP II. Design Long term follow-up assessed 10-15 years after the original trial. Setting 10 clinic sites in 1987-90 (TOHP I) and nine sites in 1990-5 (TOHP II). Central follow-up conducted by post and phone. Participants Adults aged 30-54 years with prehypertension. Intervention Dietary sodium reduction, including comprehensive education and counselling on reducing intake, for 18 months (TOHP I) or 36-48 months (TOHP II). Main outcome measure Cardiovascular disease (myocardial infarction, stroke, coronary revascularisation, or cardiovascular death). Results 744 participants in TOHP I and 2382 in TOHP II were randomised to a sodium reduction intervention or control. Net sodium reductions in the intervention groups were 44 mmol/24 h and 33 mmol/24 h, respectively. Vital status was obtained for all participants and follow-up information on morbidity was obtained from 2415 (77016), with 200 reporting a cardiovascular event. Risk of a cardiovascular event was 25% lower among those in the intervention group (relative risk 0.75, 95% confidence interval 0.57 to 0.99, P=0.04), adjusted for trial, clinic, age, race, and sex, and 30% lower after further adjustment for baseline sodium excretion and weight (0.70, 0.53 to 0.94), with similar results in each trial. In secondary analyses, 67 participants died (0.80, 0.51 to 1.26, P=0.34). Conclusion Sodium-reduction, previously shown to lower blood pressure, may also reduce long term risk of cardiovascular events.
引用
收藏
页码:885 / 888B
页数:6
相关论文
共 50 条
  • [1] The effects of dietary sodium reduction on cardiovascular disease: Long-term follow-up of the trials of hypertension prevention
    Cook, Nancy R.
    Cutler, Jeffrey A.
    Obarzanek, Eva
    Buring, Julie E.
    Rexrode, Kathryn M.
    Kumanyika, Shiriki K.
    Appel, Lawrence
    Whelton, Paul K.
    JOURNAL OF HYPERTENSION, 2006, 24 : 141 - 142
  • [2] Sodium excretion in the trials of hypertension prevention (TOHP) and subsequent cardiovascular disease
    Cook, NR
    Cutler, JA
    Obarzanek, E
    Buring, JE
    Rexrode, KM
    Whelton, PK
    CIRCULATION, 2005, 112 (17) : U895 - U896
  • [3] Follow-up of the TOHP randomized sodium reduction interventions for subsequent cardiovascular disease and mortality
    Cook, N.
    Cutler, J.
    Obarzanek, E.
    Buring, J.
    Rexrode, K.
    Kumanyika, S.
    Appel, L.
    Whelton, P.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 163 (11) : S40 - S40
  • [4] Joint Effects of Sodium and Potassium Intake on Subsequent Cardiovascular Disease The Trials of Hypertension Prevention Follow-up Study
    Cook, Nancy R.
    Obarzanek, Eva
    Cutler, Jeffrey A.
    Buring, Julie E.
    Rexrode, Kathryn M.
    Kumanyika, Shiriki K.
    Appel, Lawrence J.
    Whelton, Paul K.
    ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (01) : 32 - 40
  • [5] Joint effects of sodium and potassium intake on subsequent cardiovascular disease: The trials of hypertension prevention follow-up study
    Cook, Nancy R.
    Obarzanek, Eva
    Cutler, Jeffrey A.
    Buring, Julie E.
    Rexrode, Kathryn M.
    Kumanyika, Shiriki K.
    Appel, Lawrence J.
    Whelton, Paul K.
    CIRCULATION, 2008, 117 (11)
  • [6] Weight loss in the trials of hypertension prevention (TOHP) and subsequent cardiovascular disease
    Cook, N
    Rexrode, K
    Buring, J
    Cutler, J
    Obarzanek, E
    Whelton, P
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 159 (11) : S106 - S106
  • [7] LONG-TERM FOLLOW-UP OF CARDIOVASCULAR OUTCOMES IN KAWASAKI DISEASE. OBSERVATIONAL STUDY FROM A SINGLE CENTER
    Prieto-Pena, D.
    Luis Martin-Varillas, Jose
    Sanchez Bilbao, Lara
    Pena Sainz-Pardo, Eva
    Calderon-Goercke, Monica
    Palmou-Fontana, Natalia
    Teresa Viadero, Maria
    Jesus Cabero, Maria
    Gonzalez-Gay, Miguel A.
    Blanco, Ricardo
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1345 - 1346
  • [9] Long-Term Child Follow-up of the Pravastatin for Prevention of Preeclampsia Pilot Trials
    Costantine, Maged M.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2022, 226 (01) : S74 - S75